I Can Only Imagine

I can only imagine my wife’s beautiful face.  Oh sure, I’ve touched it and kissed it many times.  I’ve felt the lines with the tips of my fingers, tracing our lives together, and I’ve heard her smile.  I understand that’s not really seeing it.  It’s not seeing her eyes as they sparkle with something funny I said; or, when she looks at me with love reserved only for those who are truly in love.

She’s often tried to explain the flash and colors of a sunset and the cotton softness of clouds as they drift across the sky.  And, what about a rainbow made up of all the colors that somehow promise all of us that things in the world will get better. 

How amazing it would be to see my daughter Blythe skiing her favorite Colorado Mountain trail or my son Tom riding a California wave, both so secure and happy enjoying the sports they love. 

There is so much more I wish I could see, but it’s not going to happen because I am blind.  I am left with only imagining what it’s like to have the gift of sight.

I can only empathize with how a person feels when their vision is threatened by glaucoma or diabetic retinopathy, retinitis pigmentosa, and the most devastating of all, macular degeneration.

At the Discovery Eye Foundation (DEF) our researchers are working every day to overcome the loss of vision and preserve your ability to treasure all the beauty that surrounds you.  I’ve heard it said that the eyes are the windows to the soul.  I don’t know if that’s true, but I am sure that they are the single most important sense in the group of five, and that saving vision is a cause that must be supported.

DEF is committed to that mission, and with your help, answers to all forms of eye disease will be discovered.  It’s up to all of us to support the research that’s bringing us ever closer to those solutions.

If you want to help, please click the button below or download donation form to donate by mail, click here: DEF donation form

DonateNow 

 

 

Tom Sullivan
DEF’s Ambassador of Vision
sullivanvision.com

A New Commitment to Vision

Meet Tom Sullivan – DEF’s Ambassador of Vision

Over the last 40 years, I’ve been committed to working on behalf of blind children and their families.  My involvement has spanned the entire gamut of participation – from direct involvement in the classroom and counseling parents to hosting organized 10K races and celebrity golf tournaments that carried my name.  In that time, my wife and I raised just over $8 million thanks to the generosity of so many people.  Though my commitment to this cause has not changed, I’ve chosen to take on a new challenge that has in every way re-energized my passion. 

I’ve recently become the Ambassador of Vision for the Discovery Eye Foundation (DEF), a remarkable organization that funds cutting edge research that I believe someday will eliminate many forms of blindness.  The principle reason for my enthusiastic commitment is largely due to the fact that DEF directly funds researchers and avoids institutional restrictions.

As of this blog, DEF is engaged in ongoing efforts to understand 5 main eye diseases – Retinitis Pigmentosa, Macular Degeneration, Keratoconus, Diabetic Retinopathy, and Glaucoma.  I can honestly tell you that breakthroughs are not only on the horizon, but in many cases they are imminent.  Over the weeks and months I’ll be telling you much more, specifically about our individual research projects.  

Any help you may choose to give on behalf of people struggling with vision loss will be deeply appreciated. I look forward to having many of you join my fight for sight. Your help can make a difference! Click here to donate.

 

Tom Sullivan
DEF’s Ambassador of Vision
sullivanvision.com

 

 

A Second Vision

Kristin McDonald

For the last few years Kristin McDonald, a former actress and television spokeswoman, has been applying her make-up without the aid of her eyes due to retinitis pigmentosa, a condition that reduces a person’s peripheral vision until all that is left is a pinpoint of sight.

Today, she is in a first stage study that is offering her and others hope that the injection of stem cells might be the mechanism that could slow, and maybe even halt the effects of this horrible disease. Discovery Eye Foundation helped support many of the preliminary translational studies necessary to bring the clinical trial to the FDA and get this exciting, novel approach to the patients.

I am Tom Sullivan, Ambassador of Vision for the Discovery Eye Foundation, and I was rocked when my phone rang recently and I heard the sound of my friend Kristin crying.

“What’s the matter?” I asked with real concern.

Her tears were quickly replaced by laughter, joyous laughter.

“It might be working,” she said, “I mean, the cells just might be having an impact.”

“Meaning your feeling change in your vision?” I asked. 

“Tom,” she went on, “you won’t believe it. This morning when I was getting dressed and putting on my make-up, I saw my mascara in the mirror. Listen, I am not trying to tell you I can see, but since the cells were injected, I can focus on a light and even begin to notice shadows.”

“And, now,” she laughed again, “maybe I can put my mascara on straight!”

Kristin has no illusions about how far the injection of cells will take her; but, she is encouraged, as are many of the other patients who are part of Dr. Henry Klassen’s clinical study helped by DEF’s early stage funding.  Maybe the old phrase really does apply – you probably know the one I mean – “hope springs eternal in the human breast.” That goes for the researchers, the patients, and all of us who treasure the gift of sight.

To read more about Kristin McDonald, visit her website at secondvision.net

 

Tom Sullivan
DEF’s Ambassador of Vision
sullivanvision.com

Stem-Cell Clinics for AMD Treatments: Choose Wisely

People considering stem-cell therapy for eye-related issues need to take precautions in choosing clinics at which to have their procedures, warned Ocular Surgery News in January 2017. Patients should “find clinics that are licensed, associated with an academic center, have a history of running clinical trials and do not require patients to pay out of pocket.”

genetic research abstract blue background 3d illustration In a presentation to the American Society of Retina Specialists, Dr. Ajay E. Kuriyan of the University of Rochester reported that three patients who underwent bilateral intravitreal injection of stem-cells for age-related macular degeneration (AMD) suffered bilateral vision loss. The clinic at which all three procedures were performed did not have a licensed ophthalmologist on-site, and the stem-cell injections were administered by a nurse practitioner, Ocular Surgery News reported. Each patient paid $5,000 for the procedure.

Kuriyan told Ocular Surgery News that there are several warning signs for potentially dangerous clinics, including whether the facility is a standalone clinic that is not affiliated with an academic institution or has no history of conducting clinical trials. The other big warning sign, he said, is if patients are asked to pay.

“Stem-cell treatments hold great promise for the treatment of AMD and other eye conditions,” DEF Medical Director Dr. Anthony Nesburn said. “Patients — and physicians — need to take great care in choosing the right studies in which to access such treatments.”

Lauren Hauptman

Drugs to Treat Dry AMD and Inflammation

12/2/14

Below is an article from the monthly Macular Degeneration Partnership E-Update on potential drugs to treat dry AMD and inflamation. To learn more about dry AMD, including stem cell treatments, go to AMD.org. You can also subscribe and have the monthly newsletter delivered to your inbox.clinical trials for drugs to treat dry age-related macular degeneration

There are many causes of age-related macular degeneration and any of them may prove a good target for treatment for dry AMD. A long list of these was discussed at the recent Academy of Ophthalmology meeting. They were divided into the types of drugs being studied. We’ll look first at inflammation and the complement factor system, which is part of the immune system.

Inflammation is known to be associated with macular degeneration. The target may be the inflammation itself, or the cause of the inflammation.

Lampalizumab (or anti-Factor D) is a drug that is injected into the eye. In earlier Phase II trials, it was shown to reduce the area of the geographic atrophy by 20%. A Phase III clinical trial is now underway for individuals with geographic atrophy from dry AMD. Several research sites are actively recruiting now and many others will start recruiting in the near future. For more information and a list of participating centers, visit Clinical Trials.

LFG316 is also an antibody and an injection. This Phase 2 study is a randomized clinical trial of a drug that targets the C5 complement pathway (part of our immune system). It is designed to test the safety and efficacy of different doses of LFG316. There are three arms in the study: one group receiving a higher dose of the drug; one group receiving a lower dose of the drug; one group receiving a sham injection (no drug). These are successive monthly injections for people with geographic atrophy (GA). It is taking place in multiple locations throughout the U.S. and is sponsored by Novartis. For more information and a list of participating centers, visit Clinical Trials.

Oracea is a pill for dry macular degeneration, now in Phase II/III clinical trials around the U.S.. The pill contains doxycyline, which suppresses inflammation. Participants will be randomly assigned to either receive the drug or a placebo. More information at Clinical Trials.

Zimura by Ophthotech has been tested as a drug for wet AMD, but also seems to affect the drusen of dry AMD. Zimura targets the complement pathway plays a significant role in dry AMD. A Phase 2/3 clinical trial investigating ZimuraTM for treatment of geographic atrophy, is in the planning stages.

Eculizumab was also presented. This intravenous treatment for dry AMD did not show the desired effect in clinical trial, so no further development is planned at this time.

POT-4 is another drug that targets the complement factor system involved in inflammation. It is delivered through injection into the eye. The Phase I trial is completed and a Phase II clinical will be announced soon.

Iluvien is a drug delivery system that has been used in patients with diabetic retinopathy. A Phase II clinical trial for dry AMD is underway, though it is no longer recruiting patients. This is an implant inside the eye that releases fluocinolone acetonide. For more information, see Clinical Trials.

Judi Delgado - age-related macular degenerationJudith Delgado
Executive Director
Macular Degeneration Partnership
A Program of the Discovery Eye Foundation

The Evolving Contact Lens

4/22/14

Contact lenses give a person the ability to see without glasses. If you have keratoconus, they are essential for seeing as regular glasses don’t work with an irregularly shaped cornea. But lately these relatively simple lenses have created a whole new world where they can dispense eye medication, measure blood glucose levels and even help the blind see.

Courtesy Google
Courtesy Google

Monitoring Blood Sugar
You have heard about Google Glasses, but Google is looking beyond the smartphones of eye wear to monitoring health. They are currently working on a lens with tiny wireless chips and glucose sensors that are sandwiched between two lenses. They would monitor glucose levels once a second and use tiny LED lights, also inside the lenses, to flash when the levels are too high or low. And how big are these electronics? They are no larger than a speck of glitter, with a wireless antenna that is thinner than a human hair. While they are still in development – Google has run clinical research studies and is in discussions with the FDA – it could make blood sugar monitor far less invasive than pricking your finger several times a day.

Drug Delivery for Glaucoma
Getting glaucoma patients to regularly use their eye drops to regulate the pressure in their eyes has always been a problem. They forget, don’t want to be bothered, or have a hard time getting the drops into their eyes. This could change with two research projects exploring the use of contact lenses to deliver medication over a prolonged period of time.

Researchers at Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology, Boston Children’s Hospital, and the Massachusetts Institute of Technology who are working on a lens designed with a clear central area and a drug-polymer film made with the glaucoma drug latanoprost, around the edge to control the drug release. These lenses can be made with no refractive power or the ability to correct the refractive error in nearsighted or farsighted eyes.

Another team from University of California, Los Angeles have combined glaucoma medication timolol maleate with nanodiamonds and embedded them into contact lenses. When the drugs interact with the patient’s tears, the drugs are released into the eye. While the nanodiamonds strengthen the lens, there is no difference in water content so they would be comfortable to wear and allow oxygen levels to reach the eye.

Seeing in the Dark
Researchers out of the University of Michigan have developed an infrared sensor that could eventually be used in the production of night vision contact lenses. Thanks to graphene, a tightly-packed layer of carbon atoms, scientists were able to create a super-thin sensor that can be stacked on a contact lens or integrated with a cell phone.

Stem Cells for Cornea Damage
Researchers in Australia are working on a way to treat corneal damage with stem cell infused contact lenses. Stem cells were taken from the subject’s good eye and then plated them onto contact lenses (if there is a defect in both eyes, stem cells are taken from a different part of the eye). After wearing for about two weeks the subjects reported a significant increase in sight.
Braille-Tracile-Contacts
Helping the Blind See
And what good are contact lenses if you are blind? At Bar Ilan University in Israel researchers are creating special lenses that translate images into sensations felt on the eye. It works by taking an image with a smartphone or camera, it is then processed and sent to the contact lens. The custom-made lens is fitted with a series of electrodes that use small electric impulses to relay shapes onto the cornea, similar to braille. After some practice, test subjects were able to identify specific objects.

In expanding the uses of contact lenses, these projects seem to be just the beginning, all reported in the first four months of this year. Researchers and developers are working together to find more and better ways help with vision and medical issues, using contact lenses.

Susan DeRemerSusan DeRemer, CFRE
Vice President of Development
Discovery Eye Foundation